Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    CYCC   US23254L3069

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/26/2015 02/27/2015 03/02/2015 03/03/2015 03/04/2015 Date
1.09(c) 1.5(c) 1.69(c) 1.42(c) 1.1(c) Last
2 805 207 24 335 241 12 865 380 2 686 580 4 317 637 Volume
+51.39% +37.61% +12.67% -15.98% -22.54% Change
More quotes
Company
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company.It engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.Its most advance product candidate, is the subject of SEAMLESS, a phase 3 trail being... 
More about the company
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | CYCC | US23254L3069 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 1,50 M
EBIT 2014 -23,7 M
Net income 2014 -21,6 M
Debt 2014 -
Yield 2014 -
Sales 2015 -
EBIT 2015 -27,8 M
Net income 2015 -27,7 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 16,8x
Capi. / Sales 2015 0
Capitalization 25,3 M
More Financials
Latest news on CYCLACEL PHARMACEUTICALS I
03/04 CYCLACEL PHARMACEUTICALS : Entry into a Material Definitive Agreement, Other Eve..
03/04 Cyclacel Pharmaceuticals Announces Pricing of Public Offering of Common Stock
03/03 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
02/20 CYCLACEL PHARMACEUTICALS : Other Events (form 8-K)
02/06 CYCLACEL PHARMACEUTICALS : Notice of Delisting or Failure to Satisfy a Continued..
02/03 Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Con..
01/06 Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conferen..
2014 CYCLACEL PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form..
More news
Sector news Bio Therapeutic Drugs
01:51a AbbVie to buy Pharmacyclics for $21 billion to boost cancer drugs pipeline
01:51a AbbVie to buy Pharmacyclics for $21 billion to boost cancer drugs pipeline
01:25a JOHNSON & JOHNSON : What the other papers say this morning
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF